Sequenom Shares Rise on Upgrade | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Sequenom's shares were up 19 percent in Tuesday afternoon trade after investment bank Lazard Capital Markets upgraded the stock to "buy" from "hold."

Sean Lavin, an analyst for Lazard who covers the firm, issued a research note today upgrading the rating and increasing the price target on Sequenom's shares to $13.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.